Prescription medicine
Choriogonadotropin alfa Brand names: Pregnyl, Ovidrel
Choriogonadotropin alfa (Pregnyl) is a prescription medicine with an FDA approval on record since 2000. No generic is listed; pharmacies paid $485.43 per mL (Ovidrel 250 mcg/0.5 mL syrg) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the choriogonadotropin alfa FDA label on DailyMed (effective December 26, 2023, EMD Serono, Inc.); the BLA 21149 record on Drugs@FDA; every choriogonadotropin alfa label on DailyMed.
Highlights of the record
FDA label of December 26, 2023; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageOvidrel ® PreFilled Syringe (choriogonadotropin alfa injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program such as in vitro fertilization and embryo transfer.
Forms and strengths
- 0.5ml
Kit; injection (solution).
On the market
- Earliest approval on file
- September 20, 2000 Ovidrel, Emd Serono; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 3 of which 0 under generic applications, 3 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $485.43 per mL Ovidrel 250 mcg/0.5 mL syrg
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 2,355 through July 30, 2026
What is choriogonadotropin alfa used for?
From the label: indications and usageOvidrel ® PreFilled Syringe (choriogonadotropin alfa injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program such as in vitro fertilization and embryo transfer. Ovidrel ® PreFilled Syringe is also indicated for the induction of ovulation (OI) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure. […]
FDA pharmacologic class: Gonadotropin.
Source: FDA drug label (Ovidrel), EMD Serono, Inc., effective December 26, 2023 (SPL set a683e58a-63ea-44b8-a326-1a99a537bcf2), via openFDA; the full label on DailyMed
Is there a generic for choriogonadotropin alfa (Pregnyl)?
No generic choriogonadotropin alfa is approved (Drugs@FDA, October 8, 2026).
- 2000 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for choriogonadotropin alfa (Pregnyl)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $485.43 per mL (Ovidrel 250 mcg/0.5 mL syrg), about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Pregnyl 10,000 unit vial (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ovidrel 250 mcg/0.5 mL syrg | Brand | $485.43 per mL | n/a | -0.4% |
| Pregnyl 10,000 unit vial | Brand | $171.53 per vial | n/a | -0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the choriogonadotropin alfa label say about other medicines?
The choriogonadotropin alfa label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Estradiol | warnings | Safe and effective induction of ovulation and use of Ovidrel ® PreFilled Syringe in women requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. |
Source: FDA drug label (Ovidrel), EMD Serono, Inc., effective December 26, 2023 (SPL set a683e58a-63ea-44b8-a326-1a99a537bcf2), via openFDA; the full label on DailyMed
What do FAERS reports show for choriogonadotropin alfa?
The FDA Adverse Event Reporting System holds 2,355 reports that list choriogonadotropin alfa among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 34 are coded as a death and 713 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other gonadotropins
- the pharmacologic class, with prices and generics
- Choriogonadotropin alfa side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other